E. David Crawford, MD, Editor-in-Chief
LEARNING CENTERS
LATEST CONTENT
Sigrid V. Carlsson, MD, PhD, MPH, discusses the evolution of attitudes toward PSA screening for prostate cancer over time, and the importance of implementing the PSA test in a way that will truly benefit patients. She details how risk-stratifying algorithms and calculators, biomarkers, and MRI can play a role in refining prostate cancer screening.
PCa Commentary | Volume 141 - December 2019 Posted by Edward Weber | December 2019 PARP INHIBITION THERAPY — Clinical importance of genetic variants of BRCA 1/2 and ATM in men with metastatic castration-resistant prostate cancer. Something big is emerging in...
Maha H. Hussain, MD, FACP, FASCO, and Celestia S. Higano, MD, discuss the PROfound Trial, which demonstrated increased radiographic progression-free survival (rPFS) with the use of olaparib for mCRPC patients displaying the genetic mutations BRCA1, BRCA2, and ATM. Dr. Hussain outlines previous research of genetic mutations in mCRPC that led to this study, the study design and rationale of using two cohorts with specific mutations (BRCA1, BRCA2, and ATM) and non-specific mutations (other genetic alterations), and results that demonstrate promise for gene-targeted therapies in the future.
Masoom Haider, MD, provides an overview of the current state of multiparametric MRI, especially in the setting of biopsy-naive patients with elevated PSA levels. He then describes an MRI-directed biopsy pathway and how to integrate it into prostate cancer care.
David S. Morris, MD, FACS, discusses current methods of diagnosing and risk-stratifying upper tract urothelial cancer (UTUC), as well as the implications of disease risk on treatment decisions. He notes the unmet need for an effective kidney-sparing option for low-risk patients, and the potential for chemoablation with UGN-101 to address this need based on findings from the OLYMPUS trial.
E. David Crawford, MD, reviews the findings and recommendations from the Radiographic Assessments for Detection of Advanced Recurrence (RADAR) III working group, and how its prior iterations, RADAR I and II, provided the rationale for the RADAR III manuscript. He discusses the next generation imaging modalities and radiotracers covered in RADAR III, as well as the group’s consensus on how they should be implemented in the evaluation of patients with prostate cancer.
Presentations from the 4th Global Summit on Precision Diagnosis and Treatment of Prostate CancerContents: SESSION I: LEADERS OF ACADEMIA AND INDUSTRY ON ACCELERATING INNOVATION AND ITS ADOPTION IN PRECISION ONCOLOGY FOR PROSTATE CANCER: Challenges and Solutions...
